DVA Q2 Deep Dive: Flat Volumes and Policy Transitions Shape Outlook

Dialysis provider DaVita Inc. (NYSE:DVA) announced better-than-expected revenue in Q2 CY2026, with sales up 5.2% year on year to $3.55 billion. Its non-GAAP profit of $4.02 per share was 3.6% above analysts’ consensus estimates.

Is now the time to buy DVA? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

DaVita’s second quarter results surpassed Wall Street’s revenue and adjusted profit expectations, but the market response was notably negative. Management attributed this to a mix of operational and industry-specific challenges, including flat treatment volumes and sequential declines in revenue per treatment, primarily due to a less favorable commercial mix and reduced revenue from phosphate binders. CEO Javier Rodriguez emphasized, “Our growth is mainly performance clinical—that expands life, and therefore, you get the volume treatment,” highlighting improved patient mortality as a key factor. However, higher general and administrative expenses and only modest gains from recent industry consolidation contributed to investor caution.

Looking ahead, DaVita’s guidance relies on continued improvement in patient outcomes, strategic rollout of expanded dialysis therapies, and adaptation to new reimbursement policies. Management is focused on deploying expanded hemodialysis (HD) technology following recent regulatory approvals, with Rodriguez noting, “We expect to begin deploying expanded HD broadly across our network in the coming quarters.” CFO Joel Ackerman cautioned that while these clinical enhancements are expected to drive long-term volume growth, near-term financial impacts will be limited until mortality benefits materialize, likely not before 2028. The company also remains attentive to evolving Medicare payment rules and shifting patient mix, which are expected to influence profitability.

Key Insights from Management’s Remarks

Management cited improved patient mortality, operational execution, and policy transitions as key influences on Q2 performance, while also laying out strategic clinical advancements and regulatory developments.

• Improved patient outcomes: The company highlighted sustained improvements in patient mortality, which management believes are driving incremental growth in treatment volumes, even as new patient starts remain relatively flat.
• Policy and reimbursement headwinds: The transition of phosphate binders into the Medicare bundle was described as successful clinically but pressured both revenue per treatment and operational costs, with management stating that the overall impact on profitability will depend on final policy decisions later in the year.
• Expanded HD technology rollout: Recent FDA approval of a new expanded HD dialyzer enables DaVita to scale this therapy without significant capital investment, broadening access to advanced dialysis for patients and providing operational flexibility for facilities.
• Limited near-term financial impact: While expanded HD and related clinical innovations are expected to improve patient outcomes long-term, CFO Joel Ackerman noted that any financial benefits from reduced mortality will be delayed, with meaningful impacts not anticipated before 2028.
• Industry consolidation effects: The closure of competitor clinics provided only a minor increase in admits, with management seeing less-than-expected volume pickup from Fresenius’s recent clinic closures, reinforcing that DaVita’s growth is primarily driven by its own clinical initiatives rather than market exits.

Drivers of Future Performance

DaVita’s outlook is shaped by ongoing efforts to enhance patient outcomes, adapt to evolving reimbursement policies, and implement new dialysis technologies.

• Shift in patient and payer mix: Management anticipates ongoing headwinds from a declining proportion of commercially insured patients and lower Affordable Care Act (ACA) enrollment, which are expected to reduce revenue per treatment and impact overall profitability through 2027.
• Adoption of expanded HD therapies: The company plans to accelerate deployment of expanded HD dialyzers across its network, expecting this to gradually improve clinical outcomes and support long-term volume growth, although meaningful economic benefits will only be realized as mortality improvements emerge in later years.
• Regulatory and reimbursement environment: Future performance will also depend on the outcome of federal rule changes to the Medicare End-Stage Renal Disease (ESRD) payment system, with management actively engaging in the regulatory process and emphasizing that final policy decisions will determine the overall financial impact for 2027 and beyond.

Catalysts in Upcoming Quarters

In the upcoming quarters, our analysts will focus on (1) the pace at which expanded HD therapy is adopted across DaVita’s network, (2) updates to Medicare’s ESRD payment rules and their direct financial implications, and (3) whether improvements in patient mortality and volume trends translate into sustained growth. Progress in integrating new clinical technologies and navigating regulatory shifts will be pivotal for DaVita’s performance.

DaVita currently trades at $188.67, down from $227.99 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.